Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.44 |
| ▸ | F2 | P00734 | 5/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | F9 | P00740 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7524480 | 0.99 | F10 (0.43) | F10PRSS1F2HSD11B1SMN1; SMN2 | |
| SCHEMBL7525875 | 0.88 | F10 (0.47) | F10PRSS1F2HSD11B1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7526160 | 0.87 | F10 (0.46) | F10PRSS1F2HSD11B1SMN1; SMN2 | |
| SCHEMBL7528831 | 0.86 | F10 (0.46) | F10PRSS1F2HSD11B1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7525529 | 0.86 | F10 (0.45) | F10PRSS1F2HSD11B1SMN1; SMN2 | |
| SCHEMBL6834989 | 0.85 | SMN1; SMN2 (0.38) | HSD11B1SMN1; SMN2NPSR1 | |
| SCHEMBL3000890 | 0.84 | F9 (0.45) | F10PRSS1F2SMN1; SMN2F9 | |
| Hydrochloric Acid SCHEMBL6841650 | 0.84 | F9 (0.45) | F10PRSS1F2SMN1; SMN2F9 | |
| SCHEMBL6819736 | 0.81 | F10 (0.43) | F10PRSS1F2F9PLAU | |
| SCHEMBL7116247 | 0.80 | F10 (0.52) | F10PRSS1F2SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | EISERT WOLFGANG | 2009-03-19 | — | — | US | claimed |
| EP-1807086-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-07-18 | — | — | EP | claimed |
| WO-2006045756-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-04 | — | — | WO | claimed |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | claimed |
| US-20100184729-A1 | New Pharmaceutical Compositions for Treatment of Thrombosis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | EISERT WOLFGANG | 2009-03-19 | — | — | US | disclosed |
| US-20090048173-A1 | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors | EISERT WOLFGANG | 2009-02-19 | — | — | US | disclosed |
| EP-1885354-A2 | COMBINATIONS COMPRISING AT LEAST ONE DIRECT THROMBIN INHIBITOR FOR THE TREATMENT OF THROMBOSIS | Boehringer Ingelheim International GmbH (DE) | 2008-02-13 | — | — | EP | disclosed |
| EP-1807086-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1747016-A2 | USE OF DIPYRIDAMOLE FOR TREATMENT OF RESISTANCE TO PLATELET INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-01-31 | — | — | EP | disclosed |
| US-20060222640-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOSIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | US | disclosed |
| WO-2006103206-A2 | COMBINATIONS COMPRISING AT LEAST ONE DIRECT THROMBIN INHIBITOR FOR THE TREATMENT OF THROMBOSIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006045756-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-04 | — | — | WO | disclosed |
| WO-2005113006-A2 | USE OF DIPYRIDAMOLE FOR TREATMENT OF RESISTANCE TO PLATELET INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | WO | disclosed |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048173-A1 | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors | ANXA5, F5, ANXA3 | F10 112/4885PRSS1 333/4885F2 30/4885 |
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | PEPD, PLAT, TFPI | F10 51/4885PRSS1 109/4885F2 8/4885 |
| US-20100184729-A1 | New Pharmaceutical Compositions for Treatment of Thrombosis | PROC, F12, SERPINC1 | F10 6/4885PRSS1 158/4885F2 4/4885 |
| US-20060222640-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOSIS | PROC, F12, SERPINC1 | F10 6/4885PRSS1 158/4885F2 4/4885 |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | SERPINC1, TFPI, F2 | F10 30/4885PRSS1 879/4885F2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.